QNRXHIGH SIGNALFINANCIAL10-K

QNRX executed a 1-for-35 reverse stock split and is facing severe cash burn with R&D expenses nearly tripling to $9.8M while explicitly stating the need to raise additional capital to continue as a going concern.

The reverse stock split typically signals distress as companies use this mechanism to maintain exchange listing requirements when share prices fall too low. The company's explicit going concern warning combined with commentary that their October 2025 financing terms may hinder future fundraising creates significant execution risk for investors.

Comparing 2026-03-26 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

Despite raising capital that increased stockholders' equity by 42.5% to $13.1M and total assets by 29.8% to $20.4M, QNRX's cash burn accelerated dramatically with R&D expenses surging 172% and operating cash flow deteriorating 72% to -$13.5M. Net losses expanded 76% to -$15.8M, indicating the company is investing heavily in drug development but burning through cash at an unsustainable rate. The balance sheet improvements from recent fundraising are being rapidly offset by accelerating operational losses, creating urgent pressure to secure additional financing.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+172.1%
$3.6M$9.8M

R&D investment increased 172.1% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-76.3%
-$9.0M-$15.8M

Net income declined 76.3% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-72.3%
-$7.9M-$13.5M

Operating cash flow fell 72.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Stockholders Equity
Balance Sheet
+42.5%
$9.2M$13.1M

Equity base grew 42.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+34%
$14.9M$20.0M

Current assets grew 34% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
+32.7%
$4.2M$5.5M

Current liabilities surged 32.7% — significant near-term obligations; verify ability to meet short-term debt.

Total Assets
Balance Sheet
+29.8%
$15.7M$20.4M

Asset base grew 29.8% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
+11.8%
$6.5M$7.3M

Liabilities increased 11.8% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-13
ADDED
Quoin Pharmaceuticals, Ltd._December 31, 2025 http://fasb.org/srt/2025#OfficerMember http://fasb.org/srt/2025#OfficerMember http://fasb.org/srt/2025#OfficerMember http://fasb.org/srt/2025#OfficerMember http://fasb.org/srt/2025#OfficerMember 0001671502 --12-31 2025 FY Quoin Pharmaceuticals, Ltd.
As of March 23, 2026, the registrant had 63,126,930 ordinary shares, no par value per share, outstanding, and 1,803,626 ADSs outstanding (assuming all ordinary shares are represented by ADSs), with each ADS representing thirty - five (35) ordinary shares.
Effective April 9, 2025, the ratio of American Depositary Shares ( ADSs ) evidencing our ordinary shares, no par value per share ( Ordinary Shares ), changed from 1 ADS representing one (1) Ordinary Share to 1 ADS representing thirty - five (35) Ordinary Shares (the Ratio Change ), which resulted in a 1 - for - 35 reverse split of the issued and outstanding ADSs (the Reverse Split ).
Except as specifically provided, ADSs and related option, warrant, purchase price and exercise price information presented in this Annual Report, including our consolidated financial statements and the related notes, has been retroactively adjusted to reflect the Ratio Change and the Reverse Split.
We must raise additional capital to fund our operations in order to continue as a going concern.
+7 more — sign up free →
REMOVED
Quoin Pharmaceuticals, Ltd._December 31, 2024 http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember http://fasb.org/srt/2024#OfficerMember 0001671502 --12-31 2024 FY false Quoin Pharmaceuticals, Ltd.
As of March 10, 2025, the registrant had 20,585,830 ordinary shares, no par value per share, outstanding, and 20,585,830 ADSs outstanding (assuming all ordinary shares are represented by ADSs), with each ADS representing one (1) ordinary share.
Risks Related to the Discovery and Development of Product Candidates Preclinical and clinical studies of our product candidates may not be successful.
We may pursue Rare Pediatric Disease designation for QRX003 for the treatment of NS or other of our product candidates.
Other Risks Related to Our Business Operations and Industry Our future success depends on our ability to attract and retain key executives and to attract, retain and motivate qualified personnel.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →